Atea Pharmaceuticals (AVIR) Total Current Liabilities (2019 - 2026)

Atea Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $33.4 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 53.43% year-over-year to $33.4 million in Q1 2026; TTM through Mar 2026 was $33.4 million, a 53.43% increase from a year earlier, with the FY2025 full-year figure at $39.8 million, up 113.86% from the prior year.
• Total Current Liabilities eased to $33.4 million in Q1 2026 per AVIR's latest filing, from $39.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $41.3 million in Q1 2024 and bottomed at $12.4 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $21.7 million (2025), against an average of $24.4 million.
• Across the five-year window, Total Current Liabilities tumbled 94.03% in 2022 and surged 234.2% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $18.5 million in 2022, then jumped by 75.21% to $32.4 million in 2023, then sank by 42.54% to $18.6 million in 2024, then jumped by 113.86% to $39.8 million in 2025, then dropped by 16.13% to $33.4 million in 2026.
• Per Business Quant, the three latest AVIR Total Current Liabilities figures stand at $33.4 million (Q1 2026), $39.8 million (Q4 2025), and $20.2 million (Q3 2025).